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Abstract
Background: Aortic thrombosis is a rare disease and only a few cases of the disease, especially associated with
chemotherapy for malignant diseases and/or blood diseases, have been previously reported. Although Virchow’s
triad for thrombogenesis, namely hypercoagulability, blood flow stasis, and vessel wall injury, is the major factor
promoting the formation of thrombosis, the detailed mechanism of the disease has not been well established.
Case presentation: We report a case of aortic thrombosis incidentally detected by computed tomography and
then regressed by pharmacotherapy using warfarin. This case is an apparently healthy man in a postoperative state
after lung cancer surgery with decreased protein-C activity.
Conclusions: A case of aortic thrombosis without an obvious abnormality of the aorta was incidentally identified.
A few cases of aortic thrombosis in healthy aortas have been reported to be associated with chemotherapy or
blood diseases, however our present case did not had such a background. Although the detailed mechanism
remains to be elucidated, this case suggests that aortic thrombosis can develop in apparently healthy subjects with
a history of cancer surgery.
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Background
Aortic thrombosis is a rare disease and only a few cases
have been previously reported [1–3]. Malignant diseases
and/or blood diseases, such as thrombocytosis and
chemotherapy-related hematological disorders, have
been identified as one of the causes of aortic thrombosis
in these previous reports [1–5]. While Virchow’s triad
for thrombogenesis, namely hypercoagulability, blood
flow stasis, and vessel wall injury, is the major factor ac-
celerating the formation of thrombus in the aortic wall,
the detailed mechanism of aortic thrombosis has not
been fully elucidated. Moreover, its therapeutic strategy
is still controversial [6].
Previously, we reported a case of multiple aortic
thrombosis in a patient with malignant lymphoma
complicated by splenic infarction, and successfully
treated by non-invasive pharmacotherapy [7]. Since
then, we have identified another case of aortic throm-
bosis which was incidentally detected by computed
tomography (CT), when performed for follow-up of
primary diseases. Unlike our previous report, the con-
tribution of malignant disease and chemotherapy was
not suggested in this case. Here, we report a case of
aortic thrombosis with background of surgery for lung
cancer 1.5 years ago and no signature of recurrence.
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Case presentation
A 75-year-old Japanese man who had no history of throm-
bosis or thromboembolism underwent resection of his
right upper lung lobe for adenocarcinoma of localized
adenocarcinoma without distant metastasis, 2 years previ-
ously. Chemotherapy and radiation therapy were not
performed. After the operation, periodic follow-up CT
was undertaken every 6 months and fluorodeoxyglucose-
positron emission tomography (FDG-PET) was performed
after 1 year of operation in order to check for recurrence
of lung cancer, and the results showed no recurrence or
distant metastasis and no abnormality of the thoracic
aorta or unexpected mural thrombus (Fig. 1a). However,
an aortic thrombus was incidentally detected in the de-
scending aortic arch 1.5 years after the primary operation
(Fig. 1b). At that time, the patient was apparently healthy,
with a body temperature of 36.2 °C, blood pressure of
122/68 mmHg, heart rate of 76 bpm, and peripheral
oxygen saturation of 96 % in room air. Laboratory data
showed slightly elevated D-dimer, decreased plasma
protein-C activity, and normal liver function and lipid pro-
file (Table 1). Lupus anticoagulant or anticardiolipin anti-
body was not detected and the patient stopped smoking at
60-year-old (Brinkman index 800). Although the cause
and significance of decreased protein-C activity was not
fully understood, we started anticoagulant therapy for
aortic thrombosis using warfarin. Follow-up CT showed
the aortic thrombus was gradually regressing and was
eliminated completely after 6 months of anticoagulant
therapy without major complications (Fig. 1c). Then, anti-
coagulant therapy was terminated without recurrence of
aortic thrombus and plasma protein-C activity was recov-
ered within normal range (72 %).
Aortic thrombosis is a rare disease which can cause
distal embolism, but can also be detected incidentally in
asymptomatic cases [1, 2]. Although aortic mural
thrombus associated with abnormal aortic disease, such
as aortic aneurysm and aortic dissection, is often seen, a
thrombus in an apparently healthy aorta is very rare,
since the aortic blood flow is too fast for clotting and
the formation of a growing thrombus [1, 2]. Virchow’s
triad for thrombogenesis, featuring hypercoagulability,
blood flow stasis, and vessel wall injury, is known to be
important in thrombus formation, however the concept
is generally adopted for thrombosis in veins and/or small
arteries [6]. On the other hand, thromboembolism
complicated with atrial fibrillation is well-known, but
arrhythmia cannot be the etiology of local thrombus of
the aorta. Thus, the detailed mechanism of the etiology
of aortic thrombosis is not well understood [1, 2].
In the present report, we describe a case of aortic
thrombosis which was seen in an apparently healthy
man in a postoperative state after lung cancer surgery
with decreased protein-C activity. Although hereditary
protein-C deficiency is well known to be associated with
recurrent thrombosis [8, 9], this patient and his family
Fig. 1 Contrast-enhanced computed tomography (CT) of the chest undertaken 1 years after surgery for lung cancer (a) Contrast-enhanced CT of
the chest 1.5 years after surgery for lung cancer. An aortic thrombus was incidentally detected in the distal aortic arch (b) Contrast-enhanced CT
of the chest 2 years after surgery for lung cancer. The thrombus in the distal aortic arch has disappeared after 6 months of anticoagulant therapy
without an event of symptomatic distal embolism (c) Arrows indicate thrombosis
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did not have episodes of thrombosis. Moreover, the
protein-C activity was recovered within normal range
after termination of anticoagulant therapy. Protein-C
deficiency is often seen in the acute phase of thrombosis
and in patients undergoing anticoagulation therapy,
since protein-C and protein-S are vitamin K-dependent
glycoproteins that are massively lost in such conditions
[8, 9]. Thus, the contribution of protein-C deficiency to
the development of aortic thrombosis, while possible, is
not clear. Present case is in contrast to several recent
reports of aortic thrombosis which were associated
with malignant disease, hematological disorders, and
chemotherapy-related thrombosis, especially in rela-
tion to cisplatin-based chemotherapy [4, 5]. Actually,
the background of our previously reported case of
aortic thrombosis included malignant lymphoma and
related chemotherapy [6].
The therapeutic strategy for aortic thrombosis is
controversial, however, the main strategy is conservative
pharmacotherapy [1–3]. There is no definitive evidence
as to the antithrombotic therapy to be selected or the
appropriate duration of such treatment in the case of
aortic thrombosis. Therefore, we chose warfarin therapy
for 6 months in accordance with the standard therapy
in the case of venous thrombosis. After termination of
the warfarin therapy, the recurrence of aortic throm-
bosis has not been confirmed more than 6 months.
Another strategy is surgical therapy, which is particu-
larly useful for symptomatic cases with distal thrombo-
embolism, and combined therapy may also be selected
occasionally [1–3]. We selected conservative pharma-
cotherapy since signs of distal thromboembolism were
not evident. However, recently the technique of aortic
stent graft treatment has been dramatically improved,
allowing an alternative treatment choice for aortic
thrombosis, especially in emergency cases or in un-
favorable conditions [10].
Conclusions
We identified a case of aortic thrombosis without an
abnormality of the aorta. A few cases of aortic throm-
bosis in healthy aortas have been reported to be asso-
ciated with chemotherapy or blood diseases, however
our present case did not have such a background.
Although the detailed mechanism remains to be eluci-
dated, this case suggest that aortic thrombosis can
develop in apparently healthy subjects with a history
of cancer surgery.
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Table 1 Characteristics of the case
Variable Patient value Reference range
White Blood Cell (/μL) 5400 3600–9600
Hemoglobin (g/dl) 14.9 13.2–17.2
Platelet (/10−4 μL) 12.3 14.8–33.9
CK (U/L) 150 62–287
AST (U/L) 18 13–33
ALT (U/L) 17 6–30
LDH (U/L) 171 119–223
Creatinine (mg/dl) 0.89 0.60–1.10
Causal blood glucose (mg/dl) 107 70–139
Total-cholesterol (mg/dl) 165 128–219
HDL-cholesterol (mg/dl) 43 40–96
CRP (mg/dl) 0.06 <0.3
BNP (pg/ml) 31.1 < 18.4
APTT (%) 116.1 76.0–130.0
PT (%) 91.6 70.0–130.0
HbA1c (%) 6.1 4.6–6.2
D-dimer (μg/ml) 1.5 <0.5
Protein C activity (%) 45 64–146
Protein C level (%) 39 70–150
Total protein S antigen (%) 84 60–150
Free Protein S antigen (%) 91 65–135
Antithrombin III (mg/dl) 25.4 22.6–33.5
Lupus anticoagulant (second) Undetected -
Anticardiolipin antibody Undetected -
Anticardiolipin β2GPI antibodies Undetected -
CK creatine kinase, AST aspartate aminotransferase, ALT alanine aminotransferase,
LDH lactate dehydrogenase, HDL high-density lipoprotein, CRP C reactive protein,
BNP brain natriuretic peptide, APTT activated partial thromboplastin time, PT
prothrombin time, β2GPI β2 antiglycoprotein I
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